LYON, France - Adocia (Euronext Paris:ADOC) presented full results from a phase 3 clinical trial of BioChaperone® Lispro in people with type 2 diabetes in China at the American Diabetes Association’s 86th Scientific Session, which took place from Thursday to Sunday in New Orleans, according to a press release statement.
The study, designated THDB0206L02 and registered as NCT05834868, enrolled over 1,000 participants with type 2 diabetes. Topline results were initially announced in July 2025.
The trial showed non-inferior HbA1c reduction compared to Humalog®, a widely used mealtime insulin manufactured by Eli Lilly. The study reported superior long-term glycemic control in patients using Metformin or with HbA1c below 8.5%, and superior glucose control throughout the day and after each meal for the whole population. The safety profile was similar to Humalog®.
BioChaperone® Lispro was licensed to Tonghua Dongbao in 2018 for China and other Asian countries. The formulation combines Adocia’s BioChaperone® technology with insulin lispro, the active ingredient in Humalog®.
The licensing agreement includes a milestone payment of $20 million to Adocia upon marketing authorization in China, plus double-digit royalties on sales. Tonghua Dongbao is responsible for preparing the marketing authorization filing.The potential $20 million milestone represents a significant sum for the Lyon-based company, which currently holds a market capitalization of $97 million and generated $4.5 million in revenue over the last twelve months. Analysts project revenue growth of approximately 9% for fiscal 2026, with price targets ranging from $12.68 to $18.44. InvestingPro analysis indicates the stock is currently undervalued, with access to 5 additional ProTips and comprehensive financial health metrics available to subscribers.
Adocia will host a virtual event on Tuesday, June 16, 2026 at 10:00 AM EST featuring Tim Heise, MD from Profil in Neuss, Germany, to review the trial results.
The company, based in Lyon, France, employs approximately 80 people and focuses on developing therapeutic solutions for metabolic diseases including diabetes and obesity.
In other recent news, Adocia has announced it will host a virtual event to present the phase 3 trial results for BioChaperone Lispro, a treatment for type 2 diabetes. The event is scheduled for June 16, 2026, at 10:00 a.m. EST. Dr. Tim Heise, co-founder of the Profil Research Institute, will present the findings from the study conducted in China. Joining him will be Olivier Soula, CEO and co-founder of Adocia, along with You-Ping Chan, Head of R&D. These developments come as Adocia continues to focus on advancing its clinical-stage biopharmaceutical initiatives. The company has not disclosed further details about the trial outcomes ahead of the event. Investors and stakeholders are likely to pay close attention to the results, given the potential impact on Adocia’s research and development efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for ADOC plus thousands of other stocks and find your next hidden gem with massive upside.